Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report

Summary

Client: IQVIA Solutions Canada Inc.

Project ID: P2024-210 / 2025 0980 001 000

Research Question/Objectives: Transthyretin amyloidosis (ATTR amyloidosis) is a progressive and debilitating disease that can be fatal. It occurs when the transthyretin protein misfolds and accumulates as amyloid fibrils in various organs, including the heart, nerves, gastrointestinal tract, and musculoskeletal tissues.

Objectives:

1. Describe the demographics and clinical characteristics of patients with a diagnosis of transthyretin amyloidosis cardiomyopathy in Ontario from 2019 – 2023
2. Describe the incidence and prevalence of transthyretin amyloidosis cardiomyopathy in Ontario from 2019 – 2023
3. Describe the healthcare resource utilization (HCRU) and associated direct costs of patients with transthyretin amyloidosis cardiomyopathy in Ontario from 2019 – 2023

Status: In progress